PL EN


Preferences help
enabled [disable] Abstract
Number of results
2015 | 11 | 1 | 48–67
Article title

Zakrzepica w chorobie nowotworowej

Content
Title variants
EN
Thrombosis in cancer
Languages of publication
EN PL
Abstracts
EN
Malignant tumours are among the strongest risk factors for venous thromboembolism. The probability scores for deep vein thrombosis and pulmonary embolism, which we use in our everyday practice, have not yet been validated in patients with cancer, which is why they should be used with caution. Prevention of thrombosis should always be implemented in patients undergoing surgery and most patients treated conservatively, which results from the application of appropriate probability scores assessing the risk of thrombosis in these patients. The prevention method should be adjusted individually depending on the characteristics of the patient and the existence of contraindications to the use of given methods, bearing in mind their availability, cost and ability to monitor the anticoagulant effect. Treatment of venous thromboembolism in patients with cancer is different from treating it in patients with no concomitant tumour. These differences relate to both the type of treatment (anticoagulant drug selection and dosage) and its duration. Low-molecular-weight heparin is the preferred form of both initial and long-term treatment, which should last at least 6 months. Both oncologists and other health care professionals working in cancer teams should make sure at each time that the patient has at least minimal knowledge about the symptoms ensuring early detection of thrombosis. Good communication with the patient considerably facilitates effective prevention and treatment.
PL
Nowotwory złośliwe należą do najsilniejszych czynników ryzyka rozwoju żylnej choroby zakrzepowo-zatorowej. Skale oceny prawdopodobieństwa zakrzepicy żył głębokich i zatorowości płucnej, którymi się posługujemy w codziennej praktyce, nie zostały dotychczas zwalidowane u pacjentów z chorobą nowotworową, dlatego należy z nich korzystać z dużą ostrożnością. Profilaktykę przeciwzakrzepową powinno się zastosować każdorazowo w przypadku osób poddawanych zabiegom chirurgicznym oraz u większości leczonych zachowawczo, co wynika z odpowiednich skal oceny ryzyka zakrzepicy u tych chorych. Metodę profilaktyki należy dobierać indywidualnie w zależności od charakterystyki pacjenta oraz istnienia przeciwwskazań do zastosowania danych metod, mając na względzie ich dostępność, koszty oraz możliwości monitorowania efektu przeciwkrzepliwego. Leczenie żylnej choroby zakrzepowo-zatorowej u pacjentów z chorobą nowotworową różni się od leczenia pacjentów bez współistniejącego nowotworu. Różnice te odnoszą się zarówno do rodzaju leczenia (wybór leku przeciwkrzepliwego, jego dawkowanie), jak i czasu trwania terapii. Heparyna drobnocząsteczkowa jest preferowaną formą leczenia wstępnego, a także długoterminowego, które powinno trwać co najmniej 6 miesięcy. Onkolodzy wraz z pozostałym personelem służby zdrowia pracującym w teamach onkologicznych powinni każdorazowo upewnić się, że pacjent posiada przynajmniej minimum wiedzy o objawach umożliwiających wczesne wykrycie zakrzepicy. Dobra komunikacja z pacjentem zdecydowanie ułatwia prowadzenie skutecznej profilaktyki i leczenia.
Discipline
Publisher

Year
Volume
11
Issue
1
Pages
48–67
Physical description
Contributors
  • Klinika Chorób Wewnętrznych i Hematologii, Wojskowy Instytut Medyczny, Warszawa, Polska. Kierownik Kliniki: prof. dr hab. n. med. Piotr Rzepecki, tchojnacki@wim.mil.pl
  • Klinika Chorób Wewnętrznych i Hematologii, Wojskowy Instytut Medyczny, Warszawa, Polska. Kierownik Kliniki: prof. dr hab. n. med. Piotr Rzepecki
References
  • 1. Guyatt GH, Akl EA, Crowther M et al.; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel: Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl.): 7S-47S.
  • 2. Polskie wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Aktualizacja 2012.
  • 3. Shen VS, Pollak EW: Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980; 73: 841-843.
  • 4. Levitan N, Dowlati A, Remick SC et al.: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-291.
  • 5. Fijałkowska A, Szawłowski A, Wojtukiewicz M et al.: Rekomendacje Polskiego Towarzystwa Chirurgii Onkologicznej. Profilaktyka i przeciwzakrzepowe leczenie u pacjentów z nowotworami złośliwymi. Nowotwory J Oncol 2008; 58: 78-81.
  • 6. Goncerz G: Profilaktyka i leczenie żylnej choroby zakrzepowo-zatorowej u chorych na nowotwór złośliwy: podsumowanie zaleceń International Society on Thrombosis and Haemostasis. Med Prakt 2014; 10: 57-63.
  • 7. Wahrenbrock M, Borsig L, Le D et al.: Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003; 112: 853-862.
  • 8. Sack GH Jr, Levin J, Bell WR: Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56: 1-37.
  • 9. Bell WR, Starksen NF, Tong S et al.: Trousseau’s syndrome. Devastating coagulopathy in the absence of heparin. Am J Med 1985; 79: 423-430.
  • 10. Schutgens RE, Esseboom EU, Haas FJ et al.: Usefulness of a semi-quantitative D-dimer test for the exclusion of deep venous thrombosis in outpatients. Am J Med 2002; 112: 617-621.
  • 11. Baumgartner A, Jacot N, Moser G et al: Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. Vasa 1989; 18: 152-156.
  • 12. Holzheimer RG: Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur J Med Res 2004; 9: 225-239.
  • 13. Goldhaber SZ, Dunn K, Gerhard-Herman M et al.: Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002; 122: 1933-1937.
  • 14. Macdonald RL, Amidei C, Baron J et al.: Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol 2003; 59: 363-372.
  • 15. ENOXACAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84: 1099-1103.
  • 16. Ahl EA, Terrenato I, Barba M et al.: Low-molecular-weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Arch Intern Med 2008; 168: 1261-1269.
  • 17. Khorana AA, Kuderer NM, Culakova E et al.: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
  • 18. Leizorovicz A, Cohen AT, Turpie AG et al.; PREVENT Medical Thromboprophylaxis Study Group: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
  • 19. Agnelli G, Bolis G, Capussotti L et al.: A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: the @RISTOS project. Ann Surg 2006; 243: 89-99.
  • 20. Thromboprophylaxis in cancer surgery. In: Perry D, Warwick D, Gozzard D: Handbook of Thromboprophylaxis. Springer Healthcare, London 2011: 35-40.
  • 21. Bergqvist D, Agnelli G, Cohen AT et al.; ENOXICAN II Investigators: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980.
  • 22. Scottish and Collegiate Guideline Network (SIGN): Prophylaxis of Venous Thromboembolism. SIGN Publication, London 2002; 62. Available from: www.sign.ac.uk/guidelines.
  • 23. Leizorovicz A, Siguret V, Mottier D et al.: Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep in Renal Insufficiency Study (IRIS). Thromb Res 2011; 128: 27-34.
  • 24. Akl EA, Vasireddi SR, Gunukula S et al.: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; (4): CD006649.
  • 25. Lee AY, Levine MN, Baker RI et al.; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
  • 26. Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R et al.: Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism. Ann Vasc Surg 2010; 24: 628-639.
  • 27. Lim W, Dentali F, Eikelboom JW et al.: Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-684.
  • 28. Hoffmann P, Keller F: Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol 2012; 68: 757-765.
  • 29. Schulman S, Kearon C, Kakkar AK et al.; RE-COVER Study Group: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
  • 30. Bauersachs R, Berkowitz SD, Brenner B et al.; EINSTEIN Investigators: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
  • 31. Buller HR, Prins MH, Lensin AW et al.; EINSTEIN-PE Investigators: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
  • 32. Agnelli G, Buller HR, Cohen A et al.; AMPLIFY-EXT Investigators: Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
  • 33. Levine MN, Gu C, Liebman HA et al.: A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10: 807-814.
  • 34. Kearon C, Akl EA, Comerota AJ et al.; American College of Chest Physicians: Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl.): e419S-e494S.
  • 35. Carrier M, Le Gal G, Cho R et al.: Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7: 760-765.
  • 36. PREPIC Study Group: Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112: 416-422.
  • 37. Elting LS, Escalante CP, Cooksley C et al.: Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 1653-1661.
  • 38. Kristinsson SY, Pfeiffer RM, Bjorkholm M et al.: Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010; 115: 4991-4998.
  • 39. Kristinsson SY: Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010; 2010: 437-444.
  • 40. Palumbo A, Rajkumar SV, Dimopoulos MA et al.; International Myeloma Working Group: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
  • 41. Piątkowska-Jakubas B, Krawczyk-Kuliś M, Giebel S et al.: Stosowanie L-asparaginazy w leczeniu dorosłych chorych na ostrą białaczkę limfoblastyczną. Rekomendacje Polskiej Grupy ds. Leczenia Białaczek u Dorosłych. Pol Arch Med Wewn 2008; 118: 664-669.
  • 42. Mazzucconi MG, Gugliotta L, Leone G et al.: Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Blood Coagul Fibrynolysis 1994; 5: 23-28.
  • 43. Nalluri SR, Chu D, Keresztes R et al.: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285.
  • 44. Hurwitz HI, Saltz LB, Van Cutsem E et al.: Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011; 29: 1757-1764.
  • 45. Meier CR, Jick H: Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45: 608-612.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-b969df54-292a-4633-83d1-0ab0ffba6ed0
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.